NeoGenomics Publicizes Chief Monetary Officer Transition

Jeffrey S. Sherman Appointed Chief Monetary Officer

FT. MYERS, FL / ACCESSWIRE / December 5, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a number one supplier of oncology testing and world contract analysis providers, at this time introduced that Jeffrey S. Sherman will be a part of the corporate as Chief Monetary Officer, efficient December 7, 2022. Mr. Sherman succeeds William Bonello who will stay with the Firm to supply transition and onboarding assist for a time period.

“I’m happy to welcome Jeff to NeoGenomics. He brings deep monetary, healthcare and payer providers expertise from a wide range of public healthcare providers corporations. Particularly, Jeff has particularly robust abilities in pricing administration with industrial and governmental payors and income cycle administration. I am assured that Jeff will probably be an incredible asset as we return NeoGenomics to sustainable, worthwhile progress,” stated Chris Smith, Chief Govt Officer. “I recognize the collaboration I’ve had with Invoice throughout my time at NeoGenomics and need to thank him for his many contributions as a key member of the crew. I want him effectively in his future endeavors.”

Mr. Sherman brings over 32 years of finance expertise within the healthcare providers trade. Previous to becoming a member of the Firm, Mr. Sherman served because the Chief Monetary Officer of Privia Well being Group, Inc. (NASDAQ: PRVA) a nationwide doctor enablement firm that collaborates with medical teams, well being plans, and well being programs to optimize doctor practices, enhance affected person experiences, and reward medical doctors for delivering high-value care. Previous to becoming a member of Privia, Mr. Sherman served because the Govt Vice President, Chief Monetary Officer and Treasurer at HMS, a expertise, analytics and engagement options supplier serving to organizations scale back prices and enhance well being outcomes, from 2014 to 2021. Mr. Sherman was a part of the crew that helped drive a major enchancment in working efficiency at HMS throughout his tenure and led the method which resulted in a sale to Veritas-backed Gainwell Applied sciences for $3.4 billion in April 2021. Previous to that, Mr. Sherman served as Govt Vice President and Chief Monetary Officer of AccentCare, a healthcare supply group, from 2013 to 2014. Sherman beforehand served as Govt Vice President and Chief Monetary Officer of Lifepoint Hospitals, Inc. from 2009 to 2013. His expertise additionally contains senior finance positions with Tenet Healthcare Company together with Treasurer, and Divisional and Hospital CFO roles. Mr. Sherman acquired a bachelor’s diploma in Finance/Accounting from the College of Colorado, Boulder, and an MBA from the College of Southern California.

About NeoGenomics, Inc.
NeoGenomics, Inc. makes a speciality of most cancers genetics testing and knowledge providers, offering one of the complete oncology-focused testing menus on this planet for physicians to assist them diagnose and deal with most cancers. The Firm’s Pharma Companies Division serves pharmaceutical purchasers in medical trials and drug growth.

NeoGenomics is dedicated to connecting sufferers with life altering therapies and trials. We imagine that, collectively, with our companions, we may help sufferers with most cancers at this time and the following particular person recognized tomorrow. In finishing up these commitments, NeoGenomics adheres to all related knowledge safety legal guidelines, offers transparency and option to sufferers concerning the dealing with and use of their knowledge by way of our Discover of Privateness Practices, and has invested in main applied sciences to make sure the info we preserve is secured always.

Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA licensed laboratories in Fort Myers and Tampa, Florida; Aliso Viejo and Carlsbad, California; Analysis Triangle Park, North Carolina; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and CAP accredited laboratories in Rolle, Switzerland; Singapore and China. NeoGenomics serves the wants of pathologists, oncologists, educational facilities, hospital programs, pharmaceutical corporations, built-in service supply networks, and managed care organizations all through america, and pharmaceutical corporations in Europe and Asia.

Ahead-Wanting Statements
This press launch contains forward-looking statements. These forward-looking statements usually will be recognized by means of phrases similar to “anticipate,” “anticipate,” “plan,” “might,” “would,” “might,” “will,” “imagine,” “estimate,” “forecast,” “objective,” “venture,” “steering,” “plan,” “potential” and different phrases of comparable which means, though not all forward-looking statements embrace these phrases. These forward-looking statements handle numerous issues, together with statements concerning bettering operational effectivity, returning to worthwhile progress and its ongoing government recruitment course of. Every forward-looking assertion contained on this press launch is topic to a lot of dangers and uncertainties that might trigger precise outcomes to vary materially from these expressed or implied by such assertion. Relevant dangers and uncertainties embrace, amongst others, the Firm’s capability to establish and implement acceptable monetary and operational initiatives to enhance efficiency, to establish and recruit government candidates, to proceed gaining new prospects, reply to the results of the COVID-19 outbreak, supply new forms of assessments, combine its acquisitions and in any other case implement its marketing strategy, and the dangers recognized below the heading “Danger Elements” within the Firm’s Annual Report on Type 10-Ok for the 12 months ended December 31, 2021 filed with the SEC on February 25, 2022 in addition to different data beforehand filed with the SEC.

We warning buyers to not place undue reliance on the forward-looking statements contained on this press launch. You might be inspired to learn our filings with the SEC, obtainable at, for a dialogue of those and different dangers and uncertainties. The forward-looking statements on this press launch communicate solely as of the date of this doc (except one other date is indicated), and we undertake no obligation to replace or revise any of those statements. Our enterprise is topic to substantial dangers and uncertainties, together with these referenced above. Traders, potential buyers, and others ought to give cautious consideration to those dangers and uncertainties.

For additional data, please contact:
NeoGenomics, Inc.
Mark Klausner, ICR Westwicke
T: (443) 213-0501
M: (410) 627-2087

SOURCE: NeoGenomics, Inc.

View supply model on

Related posts

Proceed VAT Assortment in all States, Finance Minister Directs FIRS


Metropolis Council: Finance guide is value her worth | Information, Sports activities, Jobs


Private Finance App Rating Accumulates Wealth